Bruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.
Follow BRKR
Bruker Corporation (BRKR) Beneish M-score
Bruker Corporation's Beneish M-score for fiscal 2025 is −2.56; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.56 | (0.28) |
| FY2024 | −2.28 | (0.05) |
| FY2023 | −2.23 | (0.03) |
| FY2022 | −2.20 | 0.18 |
| FY2021 | −2.38 | 0.41 |
| FY2020 | −2.79 | (0.19) |
| FY2019 | −2.60 | (0.35) |
| FY2018 | −2.26 | 0.11 |
| FY2017 | −2.37 | 0.05 |
| FY2016 | −2.41 | 0.52 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.94 | — | 0.87 | |
| Gross margin index | 1.07 | — | 0.56 | |
| Asset quality index | 0.99 | — | 0.40 | |
| Sales growth index | 1.02 | — | 0.91 | |
| Depreciation index | 0.94 | — | 0.11 | |
| SG&A index | 1.04 | — | −0.18 | |
| Total accruals to total assets | (0.02) | — | −0.11 | |
| Leverage index | 0.87 | — | −0.28 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.56 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| GKOS Glaukos Corporation compare | −3.0× |
| HAE Haemonetics Corporation compare | −2.8× |
| SNN Smith & Nephew SNATS, Inc. compare | −2.7× |
| PODD Insulet Corporation compare | −2.6× |
| BRKR Bruker Corporation | −2.6× |
| PEN Penumbra, Inc. compare | −2.5× |
| GMED Globus Medical, Inc. compare | −2.3× |
| BIO Bio-Rad Laboratories, Inc. compare | −2.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | −2.3× |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI